Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [4]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN393663 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Vaccinia Related Kinase 2 (VRK2) (AA 260-360) antibody
- Antibody type
- Monoclonal
- Description
- This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Mouse
- Epitope
- AA 260-360
- Isotype
- IgG
- Antibody clone number
- 3B10
- Vial size
- 100 μg
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Submitted references Common variants conferring risk of schizophrenia.
Proteomics identification of nuclear Ran GTPase as an inhibitor of human VRK1 and VRK2 (vaccinia-related kinase) activities.
The C/H3 domain of p300 is required to protect VRK1 and VRK2 from their downregulation induced by p53.
Modulation of interleukin-1 transcriptional response by the interaction between VRK2 and the JIP1 scaffold protein.
Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1.
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Genetic Risk and Outcome in Psychosis (GROUP)., Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA
Nature 2009 Aug 6;460(7256):744-7
Nature 2009 Aug 6;460(7256):744-7
Proteomics identification of nuclear Ran GTPase as an inhibitor of human VRK1 and VRK2 (vaccinia-related kinase) activities.
Sanz-García M, López-Sánchez I, Lazo PA
Molecular & cellular proteomics : MCP 2008 Nov;7(11):2199-214
Molecular & cellular proteomics : MCP 2008 Nov;7(11):2199-214
The C/H3 domain of p300 is required to protect VRK1 and VRK2 from their downregulation induced by p53.
Valbuena A, Blanco S, Vega FM, Lazo PA
PloS one 2008 Jul 9;3(7):e2649
PloS one 2008 Jul 9;3(7):e2649
Modulation of interleukin-1 transcriptional response by the interaction between VRK2 and the JIP1 scaffold protein.
Blanco S, Sanz-García M, Santos CR, Lazo PA
PloS one 2008 Feb 20;3(2):e1660
PloS one 2008 Feb 20;3(2):e1660
Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1.
Blanco S, Santos C, Lazo PA
Molecular and cellular biology 2007 Oct;27(20):7273-83
Molecular and cellular biology 2007 Oct;27(20):7273-83
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- ELISA